| Biomarker ID | 1056 |
| PMID | 23358719 |
| Year | 2013 |
| Biomarker | Circulating Tumor Cells (CTC) |
| Biomarker Basis | CTC count |
| Biomolecule | Others |
| Source | Blood |
| Subjects | Humans |
| Regulation | Upregulated in patients with Lower Overall Survival (CTC count >=3) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Overall Survival |
| Type of Biomarker | Prognostic |
| Cohort | 15 healthy controls, 20 patients with Locally advanced Prostate Cancer (LaPC), metastatic castration resistant (mCRPC, n = 40) and taxane-refractory (mTRPC, n = 15) PC patients were selected |
| Senstivity | 87% |
| Specificity | 67% |
| AUC | 0.78 (95% CI: 0.6-0.9) |
| Accuracy | NA |
| Level Of Significance | p = 0.001 |
| Method Used | NA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |